ClinicalTrials.gg
CompletedNCT01860482Updated Sep 24, 2015

The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD

A Phase 4 interventional study of Newrabell® Tablet 10mg in Reflux Esophagitis, sponsored by Chong Kun Dang Pharmaceutical. Completed at 2 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-09-24.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.

02

Conditions studied

  • Reflux Esophagitis

Keywords

  • Refractory Reflux Esophagitis
  • GERD
  • Phase 4
03

In context

Esophagitis, Peptic

83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.

This study's enrollment of 39 is below the median of 135 across 60 interventional studies indexed under Esophagitis, Peptic.

Browse Esophagitis, Peptic studies →

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female aged ≥ 20 years
  2. Reflux esophagitis with erosion or ulceration confirmed by endoscopic exam.
  3. reflux esophagitis to PPIs standard treatment as follows

    1. Ongoing heartburn symptom with or without these GERD-related symptoms : Regurgitation, Non-cardiac chest pain, Epigastric pain, Belching, Bloating, Satiety, Sore throat, Cough, Laryngitis, Hoarseness, Nausea, Vomiting, Dysphagia, Odynophagia, Weight loss
    2. Ongoing heartburn symptom with or without erosion ≥ grade A according to LA Classification
  4. Ongoing heartburn symptoms ≥ 2 days during 1week right before administering first dose of IP
  5. Decided to participate and signed on an form willingly

Exclusion criteria

Exclusion Criteria:

  1. Existence of upper gastrointestinal bleeding or active gastroduodenal ulcer at screening
  2. History of operation in esophagus, stomach or duodenum
  3. The following medical history

    1. Primary esophageal motility disease, Achalasia, Scleroderma, Esophageal/pyloric stricture, Primary esophageal spasm
    2. Barrett's esophagus ≥ 3 cm
    3. Zollinger-Ellison syndrome
    4. Infectious or inflammatory bowel disease, Severe malabsorption
  4. Severe chronic heart failure, cardiovascular disease, renal failure, , asthma, liver cirrhosis
  5. History of cancer within 5 years, except completely recovered skin cancer
  6. or AST ≥ X 3
  7. Need antibiotics due to severe infection
  8. Severe medical disease that needs these prohibited medication

    • Anticoagulant(Heparin, Warfarin, etc.), High dose of aspirin(>325mg/d), Digitalis(Digoxin, etc.), Diuretics, Atazanavir, NSAIDs or
  9. Use PPIs or H2RA medicine within 1 week before administering first dose of IP, or need other PPIs or H2RA medicine during trial period
  10. Allergy or to IP or similar chemical structure(Benzimidazol derivatives, etc.)
  11. Pregnant or breast-feeding women
  12. Conversation impairment because of alcohol, drug addiction or mental illness, etc.
  13. Administration of other IP within 28 days
  14. Inability to record heartburn diary card
  15. In investigator's judgement
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Newrabell single arm

    Newrabell® Tablet 10mg b.i.d PO during 8 weeks

    Drug: Newrabell® Tablet 10mg

Interventions

06

What researchers measure

Primary outcomes

  1. Time to onset of first 1Day Heartburn free, Days

    Time frame: up to 8 weeks

Secondary outcomes

  1. Time to onset of first 2Days Heartburn free, Days

    Time frame: up to 8 weeks

  2. 1Day Heartburn free days, %

    Time frame: up to 8 weeks

  3. Time in Daytime of first Heartburn free, Days

    Time frame: up to 8 weeks

  4. Time in Nighttime of first Heartburn free, Days

    Time frame: up to 8 weeks

  5. Weekly Heartburn Improvement Rate, %

    Time frame: up to 8 weeks

  6. Average Daytime and Nighttime Heartburn Score Change at W4

    Time frame: up to 8 weeks

  7. Average Daytime and Nighttime Heartburn Score Change at W8

    Time frame: up to 8 weeks

07

Study locations

2 sites
  • Chonnam National University Hospital
    Gwangju, Donggu, Jebongro 501-757, Korea, Republic of
  • Chonnam National University Hwasun Hospital
    Gwangju, Hwasun-eup,Hwasun-gun 519-763, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2013
First posted
May 22, 2013
Start
Apr 2013
Primary completionActual
May 2015
CompletionActual
May 2015
Last update
Sep 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01860482
Responsible party
Sponsor
First posted
May 22, 2013
Start date
Apr 2013
Primary completion
May 2015
Completion
May 2015
Last update
Sep 24, 2015

Study contacts

Jongsun Rew, Ph.D
principal investigator · Chonnam National University Hospital
Sungbum Cho, Ph.D
principal investigator · Chonnam National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion